Pathogenic role of glial cells in Parkinson's disease.
Identifieur interne : 003860 ( PubMed/Corpus ); précédent : 003859; suivant : 003861Pathogenic role of glial cells in Parkinson's disease.
Auteurs : Peter Teismann ; Kim Tieu ; Oren Cohen ; Dong-Kug Choi ; Du Chu Wu ; Daniel Marks ; Miquel Vila ; Vernice Jackson-Lewis ; Serge PrzedborskiSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2003.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects), Adrenergic Agents (adverse effects), Animals, Astrocytes (drug effects), Astrocytes (pathology), Dopamine Agents (adverse effects), Glial Cell Line-Derived Neurotrophic Factor, Mice, Microglia (drug effects), Microglia (pathology), Nerve Growth Factors (administration & dosage), Nerve Growth Factors (pharmacology), Neuroprotective Agents (administration & dosage), Neuroprotective Agents (pharmacology), Oxidopamine (adverse effects), Parkinsonian Disorders (chemically induced), Parkinsonian Disorders (metabolism), Parkinsonian Disorders (pathology), Reactive Oxygen Species (metabolism), Substantia Nigra (drug effects), Substantia Nigra (metabolism), Substantia Nigra (pathology).
- MESH :
- chemical , administration & dosage : Nerve Growth Factors, Neuroprotective Agents.
- chemical , adverse effects : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Adrenergic Agents, Dopamine Agents, Oxidopamine.
- chemically induced : Parkinsonian Disorders.
- drug effects : Astrocytes, Microglia, Substantia Nigra.
- metabolism : Parkinsonian Disorders, Reactive Oxygen Species, Substantia Nigra.
- pathology : Astrocytes, Microglia, Parkinsonian Disorders, Substantia Nigra.
- chemical , pharmacology : Nerve Growth Factors, Neuroprotective Agents.
- Animals, Glial Cell Line-Derived Neurotrophic Factor, Mice.
Abstract
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive loss of the dopaminergic neurons in the substantia nigra pars compacta (SNpc). The loss of these neurons is associated with a glial response composed mainly of activated microglial cells and, to a lesser extent, of reactive astrocytes. This glial response may be the source of trophic factors and can protect against reactive oxygen species and glutamate. Alternatively, this glial response can also mediate a variety of deleterious events related to the production of pro-oxidant reactive species, and pro-inflammatory prostaglandin and cytokines. We discuss the potential protective and deleterious effects of glial cells in the SNpc of PD and examine how those factors may contribute to the pathogenesis of this disease.
DOI: 10.1002/mds.10332
PubMed: 12539204
Links to Exploration step
pubmed:12539204Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pathogenic role of glial cells in Parkinson's disease.</title><author><name sortKey="Teismann, Peter" sort="Teismann, Peter" uniqKey="Teismann P" first="Peter" last="Teismann">Peter Teismann</name><affiliation><nlm:affiliation>Neuroscience Research, Movement Disorder Division, Department of Neurology, Columbia University, New York, New York 10032, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Tieu, Kim" sort="Tieu, Kim" uniqKey="Tieu K" first="Kim" last="Tieu">Kim Tieu</name></author><author><name sortKey="Cohen, Oren" sort="Cohen, Oren" uniqKey="Cohen O" first="Oren" last="Cohen">Oren Cohen</name></author><author><name sortKey="Choi, Dong Kug" sort="Choi, Dong Kug" uniqKey="Choi D" first="Dong-Kug" last="Choi">Dong-Kug Choi</name></author><author><name sortKey="Wu, Du Chu" sort="Wu, Du Chu" uniqKey="Wu D" first="Du Chu" last="Wu">Du Chu Wu</name></author><author><name sortKey="Marks, Daniel" sort="Marks, Daniel" uniqKey="Marks D" first="Daniel" last="Marks">Daniel Marks</name></author><author><name sortKey="Vila, Miquel" sort="Vila, Miquel" uniqKey="Vila M" first="Miquel" last="Vila">Miquel Vila</name></author><author><name sortKey="Jackson Lewis, Vernice" sort="Jackson Lewis, Vernice" uniqKey="Jackson Lewis V" first="Vernice" last="Jackson-Lewis">Vernice Jackson-Lewis</name></author><author><name sortKey="Przedborski, Serge" sort="Przedborski, Serge" uniqKey="Przedborski S" first="Serge" last="Przedborski">Serge Przedborski</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2003">2003</date><idno type="RBID">pubmed:12539204</idno><idno type="pmid">12539204</idno><idno type="doi">10.1002/mds.10332</idno><idno type="wicri:Area/PubMed/Corpus">003860</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pathogenic role of glial cells in Parkinson's disease.</title><author><name sortKey="Teismann, Peter" sort="Teismann, Peter" uniqKey="Teismann P" first="Peter" last="Teismann">Peter Teismann</name><affiliation><nlm:affiliation>Neuroscience Research, Movement Disorder Division, Department of Neurology, Columbia University, New York, New York 10032, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Tieu, Kim" sort="Tieu, Kim" uniqKey="Tieu K" first="Kim" last="Tieu">Kim Tieu</name></author><author><name sortKey="Cohen, Oren" sort="Cohen, Oren" uniqKey="Cohen O" first="Oren" last="Cohen">Oren Cohen</name></author><author><name sortKey="Choi, Dong Kug" sort="Choi, Dong Kug" uniqKey="Choi D" first="Dong-Kug" last="Choi">Dong-Kug Choi</name></author><author><name sortKey="Wu, Du Chu" sort="Wu, Du Chu" uniqKey="Wu D" first="Du Chu" last="Wu">Du Chu Wu</name></author><author><name sortKey="Marks, Daniel" sort="Marks, Daniel" uniqKey="Marks D" first="Daniel" last="Marks">Daniel Marks</name></author><author><name sortKey="Vila, Miquel" sort="Vila, Miquel" uniqKey="Vila M" first="Miquel" last="Vila">Miquel Vila</name></author><author><name sortKey="Jackson Lewis, Vernice" sort="Jackson Lewis, Vernice" uniqKey="Jackson Lewis V" first="Vernice" last="Jackson-Lewis">Vernice Jackson-Lewis</name></author><author><name sortKey="Przedborski, Serge" sort="Przedborski, Serge" uniqKey="Przedborski S" first="Serge" last="Przedborski">Serge Przedborski</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2003" type="published">2003</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects)</term><term>Adrenergic Agents (adverse effects)</term><term>Animals</term><term>Astrocytes (drug effects)</term><term>Astrocytes (pathology)</term><term>Dopamine Agents (adverse effects)</term><term>Glial Cell Line-Derived Neurotrophic Factor</term><term>Mice</term><term>Microglia (drug effects)</term><term>Microglia (pathology)</term><term>Nerve Growth Factors (administration & dosage)</term><term>Nerve Growth Factors (pharmacology)</term><term>Neuroprotective Agents (administration & dosage)</term><term>Neuroprotective Agents (pharmacology)</term><term>Oxidopamine (adverse effects)</term><term>Parkinsonian Disorders (chemically induced)</term><term>Parkinsonian Disorders (metabolism)</term><term>Parkinsonian Disorders (pathology)</term><term>Reactive Oxygen Species (metabolism)</term><term>Substantia Nigra (drug effects)</term><term>Substantia Nigra (metabolism)</term><term>Substantia Nigra (pathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Nerve Growth Factors</term><term>Neuroprotective Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Adrenergic Agents</term><term>Dopamine Agents</term><term>Oxidopamine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Astrocytes</term><term>Microglia</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinsonian Disorders</term><term>Reactive Oxygen Species</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Astrocytes</term><term>Microglia</term><term>Parkinsonian Disorders</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Nerve Growth Factors</term><term>Neuroprotective Agents</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Glial Cell Line-Derived Neurotrophic Factor</term><term>Mice</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive loss of the dopaminergic neurons in the substantia nigra pars compacta (SNpc). The loss of these neurons is associated with a glial response composed mainly of activated microglial cells and, to a lesser extent, of reactive astrocytes. This glial response may be the source of trophic factors and can protect against reactive oxygen species and glutamate. Alternatively, this glial response can also mediate a variety of deleterious events related to the production of pro-oxidant reactive species, and pro-inflammatory prostaglandin and cytokines. We discuss the potential protective and deleterious effects of glial cells in the SNpc of PD and examine how those factors may contribute to the pathogenesis of this disease.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">12539204</PMID><DateCreated><Year>2003</Year><Month>01</Month><Day>22</Day></DateCreated><DateCompleted><Year>2003</Year><Month>06</Month><Day>04</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>2</Issue><PubDate><Year>2003</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Pathogenic role of glial cells in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>121-9</MedlinePgn></Pagination><Abstract><AbstractText>Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive loss of the dopaminergic neurons in the substantia nigra pars compacta (SNpc). The loss of these neurons is associated with a glial response composed mainly of activated microglial cells and, to a lesser extent, of reactive astrocytes. This glial response may be the source of trophic factors and can protect against reactive oxygen species and glutamate. Alternatively, this glial response can also mediate a variety of deleterious events related to the production of pro-oxidant reactive species, and pro-inflammatory prostaglandin and cytokines. We discuss the potential protective and deleterious effects of glial cells in the SNpc of PD and examine how those factors may contribute to the pathogenesis of this disease.</AbstractText><CopyrightInformation>Copyright 2002 Movement Disorder Society</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Teismann</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Neuroscience Research, Movement Disorder Division, Department of Neurology, Columbia University, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tieu</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Oren</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Dong-Kug</ForeName><Initials>DK</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Du Chu</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Marks</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Vila</LastName><ForeName>Miquel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Jackson-Lewis</LastName><ForeName>Vernice</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Przedborski</LastName><ForeName>Serge</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS42269</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS38370</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG13966</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS38586</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R29 NS37345</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018663">Adrenergic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495040">Gdnf protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051100">Glial Cell Line-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical><Chemical><RegistryNumber>8HW4YBZ748</RegistryNumber><NameOfSubstance UI="D016627">Oxidopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9P21XSP91P</RegistryNumber><NameOfSubstance UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018663">Adrenergic Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001253">Astrocytes</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015259">Dopamine Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051100">Glial Cell Line-Derived Neurotrophic Factor</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017628">Microglia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009414">Nerve Growth Factors</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018696">Neuroprotective Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016627">Oxidopamine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020734">Parkinsonian Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017382">Reactive Oxygen Species</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013378">Substantia Nigra</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>91</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>1</Month><Day>23</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>6</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>1</Month><Day>23</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12539204</ArticleId><ArticleId IdType="doi">10.1002/mds.10332</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003860 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003860 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:12539204
|texte= Pathogenic role of glial cells in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:12539204" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |